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After injury or cytokine stimulation, fibroblasts trans-
differentiate into myofibroblasts, contractile cells
that secrete extracellular matrix for wound healing
and tissue remodeling. Here, a genome-wide screen
identified TRPC6, a Ca2+ channel necessary and
sufficient for myofibroblast transformation. TRPC6
overexpression fully activated myofibroblast trans-
formation, while fibroblasts lacking Trpc6 were
refractory to transforming growth factor b (TGF-b)
and angiotensin II-induced transdifferentiation.
Trpc6 gene-deleted mice showed impaired dermal
and cardiac wound healing after injury. The profi-
brotic ligands TGF-b and angiotensin II induced
TRPC6 expression through p38 mitogen-activated
protein kinase (MAPK) serum response factor (SRF)
signaling via the TRPC6 promoter. Once induced,
TRPC6 activates the Ca2+-responsive protein phos-
phatase calcineurin, which itself induced myofibro-
blast transdifferentiation. Moreover, inhibition of
calcineurin prevented TRPC6-dependent transdiffer-
entiation and dermal wound healing. These results
demonstrate an obligate function for TRPC6 and
calcineurin in promoting myofibroblast differentia-
tion, suggesting a comprehensive pathway for myo-
fibroblast formation in conjunction with TGF-b, p38
MAPK, and SRF.
INTRODUCTION
Fibroblast to myofibroblast conversion plays a critical role in
wound healing and tissue remodeling after injury (Hinz, 2007;
Tomasek et al., 2002). Myofibroblasts synthesize extracellular
matrix (ECM) components and generate high contractile forces
for wound retraction or tissue remodeling in developmental pro-
cesses (Hinz, 2007). However, persistent myofibroblast activity
can underlie hypertrophic scarring, loss of tissue compliance,
and even rampant fibrosis that is the basis for fibrotic disordersDevelopmof the heart, skin, lung, kidney, skeletal muscle, and liver (Hinz,
2007; Wynn, 2008). The myofibroblast is considered a hybrid
cell type with both smooth muscle and fibroblast qualities
(Hinz, 2007). A defining feature of myofibroblast differentiation
is the formation of smooth muscle a-actin (aSMA) stress fibers
that provide a structural network for generating contractile
forces (Hinz, 2007; Tomasek et al., 2002). Myofibroblasts
synthesize ECM proteins including collagen and a specialized
fibronectin splice variant Fn-ED-A (Serini et al., 1998; Tomasek
et al., 2002).
During acute tissue injury, mesenchymal and inflammatory
cells secrete profibrotic cytokines and chemokines such as
transforming growth factor b (TGF-b), angiotensin II (AngII),
connective tissue growth factor, and endothelin-1 (ET-1) to
induce or augment myofibroblast transformation (Derynck and
Zhang, 2003; Leask, 2010). TGF-b signals through a hetero-
dimeric receptor at the plasma membrane in which a TGF-b
type 2 receptor (TGFBR2) activates a TGF-b type 1 receptor
(TGFBR1, ALK5) that then phosphorylates the transcription
factors SMAD2 and 3 in what is referred to as the canonical
pathway (Derynck and Zhang, 2003; Leask, 2010; Wynn,
2008). SMAD6 and 7 inhibit SMAD2 and 3 activity by competi-
tively binding to TGFBR1 or by enhancing receptor degradation
(Derynck and Zhang, 2003). TGF-b can also signal through non-
canonical or SMAD-independent pathways that include the
mitogen-activated protein kinase (MAPK) signaling branches,
extracellular signal-regulated kinases (ERK), c-Jun N-terminal
kinase (JNK), and p38 kinases. Both canonical and noncanonical
signaling have been implicated in myofibroblast activation and
fibrosis (Leask, 2010).
Transient receptor potential canonical (TRPC) family mem-
bers can be transcriptionally induced and/or are directly
activated by G protein-coupled receptor (GPCR) signaling
through diacylgylcerol, in addition to being more susceptible
to opening with depletion of intracellular Ca2+ stores or by
stretch of the plasma membrane (Eder and Molkentin, 2011).
TRPC channel-mediated Ca2+ influx can directly activate the
Ca2+-sensitive protein phosphatase calcineurin to program
diverse intracellular responses through its downstream tran-
scriptional effector nuclear factor of activated T cells (NFAT) (Ku-
wahara et al., 2006). TRPC6-calcineurin signaling has not been
previously implicated in regulating myofibroblast transformation
or tissue fibrosis, although one intriguing study suggested thatental Cell 23, 705–715, October 16, 2012 ª2012 Elsevier Inc. 705
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Figure 1. TRPC6 Overexpression Promotes
Fibroblast to Myofibroblast Conversion
(A) aSMA-luciferase and Postn-luciferase pro-
moter activity from cultured neonatal rat cardiac
fibroblasts transfected with expression vectors
encoding TRPC6 or IL6, or treated with recombi-
nant TGF-b (10 ng/ml).
(B) Immunofluorescent staining of aSMA (red)
-positive stress fibers and collagen I (green) in
three different fibroblast cell lines infected with
adenovirus (Ad) encoding TRPC6 or stimulated
with recombinant TGF-b. Scale bars are 50 mm.
(C) Quantification of the experiment shown in (B),
except that cardiac fibroblasts were used, as was
AngII treatment (100 nM). nR 700 cells per group.
Control (Con.) represents Adbgal infection or no
drug. *p < 0.05 versus control.
(D) Western blot for fibronectin ED-A in AdTRPC6-
infected versus uninfected control cardiac fibro-
blasts (GAPDH serves as a loading control).
(E and F) Photographs (E) and quantification (F) of
floating collagen gel matrices seeded with cardiac
fibroblasts that have contracted after 36 hr of
TGF-b stimulation or AdTRPC6 infection. *p < 0.05
versus control; n = 3 independent experiments.
Arrows in (E) show area of gel contraction.
(G) Cardiac fibroblast proliferation measured by colormetric MTT (tetrazoleum) assay 48 hr after AdTRPC6 or Adbgal (con.) infection in serum-free or
medium containing 10% fetal bovine serum (FBS). n = 3 independent experiments.
Graphical data represent the mean ± SEM. See also Figure S1.
Developmental Cell
TRPC6 Pathway for Myofibroblast Transformationendothelin-1 (ET-1)-dependent upregulation of TRPC6 via
Ga12/13 signaling actually inhibited myofibroblast formation
despite ET-1 being a profibrotic ligand (Nishida et al., 2007).
While not associated with fibrosis, TRPC6 expression and/or
activity has been implicated in podocyte cytoskeletal remodel-
ing (Wang et al., 2009), human keratinocyte differentiation
(Woelfle et al., 2010), and hippocampal neuron differentiation
(Wu et al., 2004).
RESULTS
TRPC6 Promotes Fibroblast to Myofibroblast
Transdifferentiation
To identify regulators of myofibroblast transdifferentiation, we
utilized the mammalian genome collection of expressed cDNAs
(expression plasmids) to perform a cell-based gain-of-func-
tion screen in SV40 transformed mouse embryonic fibroblasts
(MEFs). We utilized an aSMA-luciferase promoter plasmid as
a transcriptional-program surrogate for myofibroblast activation.
Less than 1% of 18,400 full-length cDNAs screened elicited
a signal greater or equal to that obtained with recombinant
TGF-b treatment. Two of the positive cDNAs identified were
the known fibroblast activator interleukin-6 (IL-6) and TRPC6
(Figure 1A). We confirmed the fibroblast-activating effect with a
second luciferase reporter plasmid containing the periostin
(Postn) promoter, which is also induced in transformed fibro-
blasts. TRPC6 overexpression induced both reporters similar
to TGF-b treatment (Figure 1A).
To investigate if TRPC6 can directly induce fibroblast to myo-
fibroblast transdifferentiation, we infected MEFs, primary rat
cardiac fibroblasts, and primary human dermal fibroblasts with
a recombinant adenovirus (Ad) expressing TRPC6 or Adbgal706 Developmental Cell 23, 705–715, October 16, 2012 ª2012 Elsev(control) and then assayed for aSMA stress fiber formation and
collagen I by confocal microscopy 48 hr later (Figures 1B and
1C). AdTRPC6 infection induced aSMA stress fiber positivity
and conversion of approximately 50% of all three types of
fibroblasts, in a manner similar to TGF-b or AngII treatment,
while less than 5% of control fibroblasts expressed aSMA (Fig-
ure 1C). AdTRPC6 infection also enhanced expression of the
myofibroblast-specific ED-A isoform of fibronectin by western
blotting (Figure 1D, Fn-EDA). A primary myofibroblast function
is to contract a collagen gel matrix (Rice and Leinwand, 2003;
Tomasek et al., 2002), and here both AdTRPC6-infected and
TGF-b-treated fibroblasts showed contraction over 36 hr, while
Adbgal-infected controls did not (Figures 1E and 1F). However,
the contraction of collagen gel matrices induced by TRPC6 over-
expression was not due to altered cardiac fibroblast proliferation
(Figure 1G).
TRPC channels form homo- or heterotetramers, although
overexpression of any one subunit alone can enhance Ca2+
currents (Eder and Molkentin, 2011). To determine if myofibro-
blast transformation was specific to TRPC6, we also evaluated
the ability of AdTRPC3 and AdTRPC4 infection to induce
aSMA expression and contract collagen matrices in primary
cardiac fibroblasts (Figures S1A–S1C available online). TRPC4
showed no effect while TRPC3 overexpression weakly con-
verted some fibroblasts to myofibroblasts, although not nearly
to the same magnitude as TRPC6.
Loss of TRPC6 Prevents TGF-b-Mediated Myofibroblast
Transformation
To determine if TRPC6 is required for myofibroblast conversion,
dermal fibroblasts isolated from Trpc6 wild-type (WT) and null
littermates (Dietrich et al., 2005) were examined for TGF-bier Inc.
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Figure 2. Loss of TRPC6 Prevents TGF-b-Mediated Myofibroblast
Conversion
(A) Immunofluorescent staining of aSMA-positive (green) stress fibers and
TOPRO-3 iodide nucleic acid stain (blue) in primary Trpc6+/+ (WT) and
Trpc6/ dermal fibroblasts, with and without recombinant TGF-b stimulation.
Scale bars are 50 mm.
(B and C) (B) Photographs and (C) quantification of contraction of floating
collagen gel matrices seeded with Trpc6+/+ or Trpc6/ dermal fibroblasts at
36 hr after TGF-b stimulation. *p < 0.05 versus control; #p < 0.05 versus
Trpc6+/+ with TGF-b; n = 3. The arrow in B shows contraction of the gel.
(D) Quantification of in vitro scratch closure rates in Trpc6+/+ and Trpc6/
fibroblast monolayers in culture in serum free (SF) and 10% fetal bovine serum
(FBS) conditions. The scratch area wasmeasured at time 0 and 24 hr later. *p <
0.05 versus Trpc6+/+; n = 3.
Graphical data represent the mean ± SEM.
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TRPC6 Pathway for Myofibroblast Transformationinduction of aSMA stress fiber formation and contractile func-
tion. Remarkably, Trpc6/ primary dermal fibroblasts showed
no induction of aSMA-positive stress fiberswith TGF-b treatment
in contrast to robust induction in similarly prepared WT fibro-
blasts (Figure 2A). Moreover, TGF-b induced profound con-
traction of collagen gels cultured with WT fibroblasts, while
Trpc6/ fibroblasts were refractory to TGF-b-mediated con-
traction (Figures 2B and 2C). Interestingly, the ability to repopu-
late a scratched confluent monolayer in culture either was
not impaired in Trpc6/ fibroblasts or was more proficient
compared with WT fibroblasts, depending on culturing condi-
tions (Figure 2D).DevelopmTRPC6 Is Necessary for Dermal and Cardiac Wound
Healing
Here, a dermal wound-healing model was employed in which
two dorsal 6 mm punch biopsies were taken from Trpc6 WT
and null littermates. Wounds were first generated in WT mice
and the healing border areas were dissected at day 4 for RT-
PCR analysis of TRPC6 mRNA. TRPC6 mRNA was dramatically
induced in the wounds from three separate mice compared with
lower levels in two uninjured control mice (Figure 3A). Consistent
with these results, Trpc6/ mice had significantly impaired
wound closure rates over time such that by day 5 when Trpc6
WT mice had highly retracted wounds, Trpc6/ mice attained
only 33.1% retraction (Figures 3B and 3C). At 3 days postbiopsy
the border zones of the wounds were stained for aSMA (myofi-
broblasts) and isolectin (endothelial cells) (Figure 3D). Trpc6/
histological sections had significantly less myofibroblasts per
area than WT counterparts, suggesting that the poor dermal
wound healing in Trpc6/ mice could be due to impaired myo-
fibroblast formation (Figures 3D and 3E).
We also examined a cardiac injury model involving myocardial
infarction (MI), asmyofibroblast transformation is critical tomain-
tain ventricular wall structural integrity and to reduce dilation.
Compared with WT mice, Trpc6/ mice had significantly higher
rates of mortality due to ventricular wall rupture throughout
3–7 days after MI injury, a time during which scar formation and
remodeling mostly occurs (Figure 3F). The Trpc6/ mice that
survived MI had significantly smaller scar sizes, greater reduc-
tions in cardiac function, and significantly greater ventricular
wall dilation compared with WT MI mice (Figures 3G–3I).
Noncanonical TGF-b Signaling Induces TRPC6 Gene
Expression to Activate Myofibroblasts
TGF-b stimulation induced mRNA levels of TRPC6 in primary
cardiac fibroblasts but not in other TRPC family members,
except for a slight increase in TRPC1 (Figure 4A). Immunofluo-
rescent analysis of cardiac fibroblasts fixed 48 hr after TGF-b
treatment also showed enhanced TRPC6 protein levels, similar
to AdTRPC6 infection (Figure 4B). Since TGF-b can mediate its
effects through canonical (SMAD2/3) or noncanonical (MAPK)
pathways, we examined these downstream effects. The TGF-
b-dependent induction of TRPC6 expression was not inhibited
by infection with AdSMAD6 or AdSMAD7, known inhibitors of
canonical signaling (Figure 4C). However, the p38 MAPK inhib-
itor SB731445 completely blocked TGF-b-dependent induction
of TRPC6 expression suggesting a critical role for noncanonical
signaling in TRPC6 induction.
Signaling by p38 MAPK is elicited by many different inflamma-
tory cytokines (not just TGF-b signaling), such as through AngII
and its receptor, which also fully induced TRPC6 gene expres-
sion in a p38-dependent manner (Figure 4C). This was par-
ticularly interesting because p38 signaling might represent
a common intracellular event in myofibroblast transformation
between diverse inflammatory cytokines and their different
receptors. Indeed, TGF-b mediated aSMA stress fiber positivity
and myofibroblast transformation was inhibited by blockade of
p38 signaling, but not by AdSMAD7 (Figures 4D and 4E).
Importantly, small hairpin RNA (shRNA)-mediated knock-
down of the ALK5 (TGFBRI) receptor that fully suppressed
TGF-b-dependent myofibroblast transformation did not inhibitental Cell 23, 705–715, October 16, 2012 ª2012 Elsevier Inc. 707
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Figure 3. TRPC6 Is Necessary for Dermal and Cardiac Wound Healing
(A) RT-PCR for TRPC6 mRNA from skin wounds of three separate mice or uninjured skin of two control mice. GAPDH is used as a control.
(B) Photographs of two full excision 6 mm dorsal coat (skin) punch biopsies taken on 8- to 10-week-old Trpc6+/+ and Trpc6/ littermates at day 0, and the
progression shown again at day 5.
(C) Quantification of dermal would closure rates. n = 8 per group. *p < 0.05 versus Trpc6+/+.
(D and E) Wound border zone pictures and quantitation at 3 days postbiopsy stained with isolectin (green) to detect epithelial cells and aSMA (red) to detect
myofibroblasts, which was quantified. Scale bars = 0.1 mm. *p < 0.05 versus Trpc6+/+; n = 4 per group.
(F) Survival curves of Trpc6+/+ (WT) and Trpc6/ (KO) littermates after sham or permanent coronary ligation surgery (MI).
(G) Quantification of scar size at 1 week after coronary ligation in surviving Trpc6+/+ and Trpc6/ mice. *p < 0.05 versus Trpc6+/+; n = 5 per group.
(H and I) M-mode echocardiographic assessment of left ventricular fractional shortening (FS %) and left ventricular end diastolic dimensions (LVED) in the
indicated groups of mice. *p < 0.05 versus WT sham; #p < 0.05 versus WT MI; n = 10–14 per group.
Graphical data represent the mean ± SEM.
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TRPC6 Pathway for Myofibroblast TransformationTRPC6-dependent transformation (Figure 4F). This result indi-
cates that TRPC6 is downstream of the TGF-b receptor complex
in mediating myofibroblast transformation, although it does not
distinguish canonical versus noncanonical signaling. Finally,
ALK5-deficient cardiac fibroblasts infected with AdMKK6, which
purely drives p38MAPK signaling, fully promoted aSMA-positive
stress fiber formation and myofibroblast transformation, similar
to AngII treatment, indicating that noncanonical p38mobilization
is the critical aspect of TGF-b signaling in forming myofibro-
blasts. This result also explains how AngII, ET-1, and select other
inflammatory cytokines can themselves drive myofibroblast
transformation without eliciting TGF-b signaling or SMAD tran-
scriptional responses (see Discussion).
SRF Directly Induces TRPC6 Gene Expression
Downstream of TGF-b-p38 MAPK Signaling
SRF and its transcriptional cofactors, myocardin andmyocardin-
related transcription factor (MRTF), are activated by TGF-b708 Developmental Cell 23, 705–715, October 16, 2012 ª2012 Elsevreceptor signaling to facilitate aSMA gene expression and myo-
fibroblast transformation (Chai et al., 2007; Crider et al., 2011;
Sandbo et al., 2009). Investigation of themouse TRPC6 proximal
promoter (1187 to +1) identified several potential SRF binding
sites, of which the most proximal promoter sequence at 123
to 114 was highly conserved (Benson et al., 2011). Here, we
determined that SRF overexpression in fibroblasts, but not
the related transcription factor myocyte enhancer factor 2a
(MEF2a), upregulated TRPC6 mRNA expression, which was
blocked with the p38 inhibitor SB731445 (Figure 5A). Transfec-
tion of a luciferase reporter plasmid containing a 1,187 bp
TRPC6 proximal promoter showed induction by TGF-b, SRF,
and synergistic activation with both together (Figure 5B). A
TRPC6 promoter deletion construct (215) containing the con-
served proximal SRF binding site (CArG box) at 123 to 114
showed over 3-fold induction with TGF-b stimulation, yet an
identical promoter construct with this site mutated was unre-
sponsive to TGF-b (Figure S2A). The induction of TRPC6ier Inc.
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Figure 4. Noncanonical TGF-b-Mediated Signaling Induces TRPC6 Gene Expression to Activate Myofibroblasts
(A) Representative RT-PCR for TRPC family members in which PCR product was sampled every five cycles starting at cycle 20 from cardiac fibroblasts ±12 hr of
TGF-b treatment.
(B) Immunofluorescent staining of TRPC6 (green) and TOPRO-3 iodide nucleic acid stain (blue) in cardiac fibroblasts treated with TGF-b or infected with
AdTRPC6.
(C) Real-time PCR for TRPC6 induction (normalized to 18sRNA) from cardiac fibroblasts that were simultaneously treated for 24 hr with profibrotic molecules
(TGF-b or AngII) ± noncanonical (p38 inhibitor, SB731445) or canonical (adenoviral SMAD6/7) inhibitors. *p < 0.05 versus media; #p < 0.05 versus control with
same treatment; n = 3 independent experiments run in duplicate.
(D and E) (D) Immunofluorescent staining and (E) quantification of aSMA-positive (green) stress fibers and TOPRO-3 iodide nucleic acid stain (blue) in cardiac
fibroblasts that were treated for 48 hr with TGF-b. Some groups also received noncanonical (p38 inhibitor, SB731445) or canonical (AdSMAD7 infection)
inhibitors as depicted. *p < 0.05 versus control; #p < 0.05 versus baseline with same treatment; n R 250 cells per group over two independent experiments.
(F) Immunofluorescent staining of aSMA expression (green) in fibroblasts expressing a scrambled shRNA control or shRNA-anti-ALK5 that were also treated
with TGF-b, AngII or infected with AdTRPC6, or AdMKK6. Nuclei are shown in blue.
Scale bars are 50 mm. Graphical data represent the mean ± SEM.
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TRPC6 Pathway for Myofibroblast Transformationpromoter activity by SRF was blocked with the p38 inhibitor (Fig-
ure 5B). Importantly, chromatin immunoprecipitation (ChIP) ex-
periments spanning 1,238 to 855 bp of the TRPC6 promoter
showed SRF binding that was induced with TGF-b but reduced
with an adenovirus expressing an shRNA against SRF, suggest-
ing direct regulation of TRPC6 gene expression (Figure 5C).
Indeed, ChIP with an anti-phospho-SRF antibody (activated
SRF) showed even greater inducible occupancy of the TRPC6
promoter upon TGF-b stimulation (Figure 5C). Similar results
were achieved by ChIP with another primer pair that amplified
the most proximal CArG element near the start site of transcrip-Developmtion (data not shown). Gel shift analysis of the proximal –123
CArG box showed optimal binding of SRF from cell extracts
that was blocked with prior infection with a recombinant adeno-
virus expressing an shRNA against SRF (Figure S2B). Collec-
tively, these results suggest that SRF can bind and directly
regulate the TPRC6 promoter in a p38-dependent manner.
AdSRF infection of primary WT dermal fibroblasts fully in-
duced myofibroblast transdifferentiation, as shown by immuno-
cytochemistry for aSMA (Figures 5D and 5E). However, Trpc6/
dermal fibroblasts were completely refractory to SRF-mediated
induction of myofibroblast transdifferentiation, indicating thatental Cell 23, 705–715, October 16, 2012 ª2012 Elsevier Inc. 709
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Figure 5. SRF Mediates TRPC6 Gene Expression and Myofibroblast Transdifferentiation
(A) Real-time PCR analysis of TRPC6 mRNA in primary cardiac fibroblasts infected with the indicated adenoviruses, with or without p38 inhibitor (SB731445).
*p < 0.05 versus Adbgal; #p < 0.05 versus AdSRF + vehicle. Results are averaged from three independent experiments.
(B) TRPC6-luciferase promoter activity (1,187bp) fromfibroblasts cotransfectedwith the indicated plasmids or treatedwith TGF-bor SB731445. *p <0.05 versus
media (untransfected); #p < 0.05 versus TGF-b or SRF; yp < 0.05 versus SRF alone.
(C) ChIP assay from the TRPC6 promoter regions (1,238 to855 bp) for SRF using a standard or phospho-specific SRF antibody. Cells were previously treated
with or without TGF-b or infected with Ad-shSRF or Ad-shGFP as a control.
(D) Immunocytochemistry for aSMA (green) in WT or Trpc6/ primary dermal fibroblasts infected with Adbgal or AdSRF. Red staining is SRF.
(E) Quantitation of percentage of aSMA converted WT or Trpc6/ fibroblasts treated with the agonist or adenovirus shown. (n = 3 experiments; *p < 0.05 versus
Adbgal WT; #p < 0.05 versus WT of the same treatment).
(F) Western blot for SRF or GAPDH in fibroblasts infected with Ad-shSRF or Ad-shGFP control.
(G) Immunocytochemistry for aSMA (green) or (H) collagen gel contraction assays in control (shGFP) or shSRF adenoviral infected primary dermal fibroblasts
treated with TGF-b, AngII, or coinfected with the indicated adenoviruses.
Scale bars are 50 mm. (n = 3 experiments; *p < 0.05 versus control; #p < 0.05 versus shGFP of the same cotreatment. NS, not significant). Graphical data represent
the mean ± SEM. See also Figure S2.
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TRPC6 Pathway for Myofibroblast TransformationTRPC6 is a required downstream mediator of SRF-dependent
myofibroblast transformation (Figures 5D and 5E). Trpc6/
primary dermal fibroblasts were also refractory to TGF-b and
AngII-mediated myofibroblast transdifferentiation, cytokines
that are known to induce SRF or MRTF activity (Martin-Garrido
et al., 2011; Small et al., 2010) (Figure 5E).
Finally, to examine the necessity of SRF in mediating TGF-b or
AngII-dependent myofibroblast transdifferentiation, we used a
recombinant adenoviral construct expressing an shRNA against
SRF (Streb and Miano, 2005). Knockdown of SRF (>80% by
western blot; Figure 5F) prevented both TGF-b and AngII-
dependent myofibroblast transdifferentiation, but, importantly,
it did not inhibit transdifferentiation mediated by AdTRPC6 as
assessed by aSMA staining or gel contraction assays (Figures710 Developmental Cell 23, 705–715, October 16, 2012 ª2012 Elsev5G and 5H). Ad-shSRF infection of primary fibroblasts also
reduced baseline TRPC6 mRNA expression, as well as blocked
TGF-b induction of expression (Figure S2C). These results
place SRF in a critical intermediary position in the transdif-
ferentiation signaling cascade, where it receives input from
TGF-b and other profibrotic cytokines through p38 MAPK sig-
naling, which then directly mediates TRPC6 gene expression
to mobilize a Ca2+-dependent pathway for transdifferentiation
(see below).
TGF-b-p38 Signaling Enhances Ca2+ through TRPC6 in
Activated Myofibroblasts
Given TRPC6’s role in Ca2+ entry, cardiac fibroblasts were either
treated with TGF-b or infected with AdTRPC6 for 48 hr and thenier Inc.
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Figure 6. TRPC6-Mediated Ca2+ Signaling Mediates Myofibroblast Transdifferentiation
(A) Quantification of SOCE for control (no treatment or Adbgal infection, n = 24), TGF-b-treated (n = 25), and AdTRPC6-infected (n = 54) cardiac fibroblasts.
*p < 0.05 versus control; three independent experiments were performed.
(B) Quantification of SOCE in Trpc6+/+ and Trpc6/ dermal fibroblasts ± 48 hr TGF-b treatment. *p < 0.05 versus control Trpc6+/+; #p < 0.05 versus TGF-b in
Trpc6+/+ fibroblasts; nR 20 cells per group derived from three independent experiments.
(C) Quantification of SOCE from control (n = 159), TGF-b-treated (n = 71), and AdTRPC6 (n = 41) -infected cardiac fibroblasts ± p38 inhibitor (n = 32) or ± AdMKK6
(n = 32). *p < 0.05 versus media under control conditions; #p < 0.05 versus TGF-b with media; consisting of over three independent experiments. (A-C) SOCE is
calculated as the difference between the peak Ca2+ signal obtained with Fura-2 during Ringer’s reperfusion and the steady-state Ca2+ level reached after CPA
treatment.
(D and E) Immunofluorescent staining (D) and quantification (E) of aSMA-positive (red) stress fibers and collagen I (green) in cardiac fibroblasts 48 hr
after adenoviral infection with Adbgal, AdTRPC6, AdDCnA, AdCain (calcineurin-NFAT inhibitor), or coinfection with AdTRPC6 + AdCain. *p < 0.05 versus Adbgal;
#p < 0.05 versus AdTRPC6; nR 750 cells per group from two independent experiments.
(F) NFAT-luciferase activity from cardiac fibroblasts infected with the reporter AdNFATx9-Luc, AdTRPC6, AdDCnA or treated with recombinant TGF-b. *p < 0.05
versus control; n = 3 independent experiments.
(G) Immunofluorescent staining of aSMA- (red) positive stress fibers and the localization of NFAT-GFP in cardiac fibroblasts coinfected with AdNFATc1-GFP and
AdTRPC6, AdDCnA, or treated with TGF-b. Arrows indicate fibroblasts that have aSMA stress fibers and NFAT in the nucleus.
Graphical data represent the mean ± SEM. See also Figure S3.
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TRPC6 Pathway for Myofibroblast Transformationstore-operated calcium entry (SOCE) was measured. Represen-
tative traces and quantification of the intracellular Ca2+ signal
showed significant increases with AdTRPC6 and with 48 hr of
TGF-b and AngII compared to no treatment (Figures 6A and
S3A). This increase in SOCE was not due to acute TGF-b
signaling since 15 min of ligand treatment had no effect, sug-
gesting it was likely mediating transcriptional changes.
Relative to WT dermal fibroblasts that demonstrated a nearly
2-fold increase in SOCE with TGF-b treatment, Trpc6/ fibro-
blasts had no change, indicating that TRPC6 is the primary
mediator of the TGF-b-dependent enhancement of SOCE in
activated fibroblasts (Figure 6B). Moreover, this TGF-b-depen-
dent increase in SOCE in fibroblasts was significantly reduced
with a p38 MAPK inhibitor, while unitary activation of p38
with AdMKK6 infection induced a small, albeit significant in-
crease in SOCE (Figure 6C). These results support the overallDevelopmmodel whereby noncanonical TGF-b signaling through p38
enhances myofibroblast transformation through a Ca2+ signal
that uniquely depends on Trpc6 gene expression. However,
these results do not establish that SOCE is the mechanism
behind TRPC6’s ability to convert fibroblasts (SOCE was simply
a surrogate assay for TRPC function), as TRPC channels can
also mediate Ca2+ influx independent of store depletion (see
Discussion).
TRPC6-Dependent Ca2+ Induces Calcineurin-NFAT for
Myofibroblast Transformation
TRPC channels mediate their biologic effects primarily through
Ca2+ influx and Ca2+-dependent signaling effectors, of which
calcineurin-NFAT has been particularly implicated (Kuwahara
et al., 2006). Indeed, nearly 50% of cardiac fibroblasts infected
with a recombinant adenovirus expressing a constitutively activeental Cell 23, 705–715, October 16, 2012 ª2012 Elsevier Inc. 711
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TRPC6 Pathway for Myofibroblast Transformationcalcineurin (DCnA) mutant showed aSMA-positive stress fibers
similar to TRPC6 overexpression (Figures 6D and 6E). Coinfec-
tion of TRPC6 with the calcineurin-NFAT inhibitor Cain fully
blocked this conversion while Cain alone had no effect (Figures
6D and 6E). Moreover, inhibition of calcineurin with Cain or
specific inhibition of only NFAT with VIVIT blockedmyofibroblast
formation and collagen gel contraction in cardiac fibroblasts
stimulated with TGF-b or AdTRPC6 (Figure S3B). Ppp3r1 (calci-
neurin B1) null MEFs (lack all calcineurin activity) were also
unable to contract a collagen gel after TGF-b or AdTRPC6 infec-
tion (Figure S3C). Taken together, these results indicate that
activation of calcineurin is sufficient to drive myofibroblast trans-
differentiation and that calcineurin signaling is necessary for
TRPC6- and TGF-b-dependent formation of myofibroblasts.
TRPC6 overexpression caused a 12-fold increase in NFAT
activity (Figure 6F) that could be blocked by Cain (data not
shown). AdDCnA was used as a positive control yielding a 50-
fold induction of NFAT activity (Figure 6F). TGF-b also elicited
a significant increase in NFAT activity, although it was only
2-fold above baseline (Figure 6F). A more sensitive assay
involving NFAT translocation showed a remarkable association
between NFAT and TRPC6/TGF-b signaling. Specifically,
NFATc1-GFP normally resides in both the cytoplasm and
nucleus of quiescent fibroblasts, while infection with AdDCnA
sends all the NFATc1-GFP to the nucleus (Figure 6G). Both
TGF-b and TRPC6 specifically sent essentially all of the
NFATc1-GFP to the nucleus only in those fibroblasts that had
converted to myofibroblasts with aSMA positivity (Figure 6G).
Placing this result within the hierarchy of the larger signaling
pathway, we also observed that AdDCnA-inducedmyofibroblast
transformation was independent of p38MAPK since the inhibitor
did not reduce aSMA positivity (Figure 6E). Moreover, inhibition
of SRF with an shRNA against SRF did not block the ability
AdDCnA to inducemyofibroblast transdifferentiation (Figure 5G).
Finally, TGF-b stimulation also increased expression of calci-
neurin AbmRNA levels, which enhances total calcineurin activity
(Figures S3D and S3E).
WT or Trpc6/ fibroblasts infected with AdDCnA each
showed robust gel contraction, similar to AdTRPC6 infection
(Figures 7A and 7B). As a control, TGF-b was still unable to elicit
contraction in collagen gels containing Trpc6/ fibroblasts
(Figures 2B and 7B). Collectively, these results indicate that
calcineurin-NFAT signaling is downstream of the TGF-b-p38
MAPK-SRF signaling event that mediates enhanced TRPC6
expression/activity. These results define the ability of calcineurin
to drive myofibroblast transformation as the downstream medi-
ator of TRPC6.
The TRPC6-Calcineurin-NFAT Signaling Axis Is
Necessary for Dermal Wound Healing
Since DCnA overcame the defect in myofibroblast collagen gel
contraction with loss of Trpc6, we hypothesized that activated
calcineurin would restore defective wound healing in Trpc6/
mice. To examine this hypothesis AdDCnA, AdTRPC6 or AdGFP
(as an internal control) was topically applied to dermal punch
biopsies in WT and Trpc6/ mice (Figure 7C). AdDCnA signifi-
cantly improved the rate of wound closure in Trpc6/ mice at
each designated time point, similar to or even slightly better
than AdTRPC6, while AdGFP infection had no effect (Figures712 Developmental Cell 23, 705–715, October 16, 2012 ª2012 Elsev7C and 7D). Consistent with this result, Ppp3cb/ (calcineurin
Ab) mice had significantly impaired dermal wound closure rates
at days 4–7, although by day 10 healing eventually caught up to
WT controls (Figure 7E). Similarly, WT mice treated with tacroli-
mus (FK506), a calcineurin inhibitor, showed a mild but signifi-
cant impairment in wound healing, as previously suggested in
the literature (Gisquet et al., 2011; Scha¨ffer et al., 1998; data
not shown). By comparison, Trpc6/mice had amore profound
wound closure defect that never resolved even up to 10 days
postinjury (Figure 7E).
DISCUSSION
Here we discovered a previously unrecognized function for
TRPC6-calcineurin-NFAT signaling in myofibroblast transfor-
mation and wound healing in vivo. This TRPC6-calcineurin-
NFAT pathway is mobilized by p38 MAPK, a nodal stress-
induced and proinflammatory signaling effector that functions
downstream of noncanonical TGF-b signaling and other GPCR
agonists that mediate fibrosis (Figure 7F). This profibrotic cyto-
kine signaling pathway mobilizes the transcriptional activity of
SRF, which, in turn, mediates myofibroblast transdifferentiation
through its ability to specifically upregulate TRPC6 gene expres-
sion. The most profound observation of our study was that
singular activation of TRPC6 or calcineurin fully mediates myofi-
broblast transformation without TGF-b or other profibrotic cyto-
kines, as well as without SRF. Moreover, loss of Trpc6 fully
inhibited myofibroblast transformation in vitro, regardless of
the stimulating profibrotic ligand used or if SRF was overex-
pressed. We also demonstrated that calcineurin-NFAT is
necessary for TRPC6-mediated Ca2+ influx in programming
myofibroblast transformation (Figure 7F). NFAT has been shown
to regulate aSMA expression in activated pulmonary myofibro-
blasts (Rice and Leinwand, 2003). Also, aSMA, fibronectin and
collagen gene expression can all be activated by NFAT signaling
(Cobbs and Gooch, 2007; Gonzalez Bosc et al., 2005; Le´jard
et al., 2007).
Role of Noncanonical Signaling and p38 MAPK in
Myofibroblast Transformation
Myofibroblast transformation is elicited by an array of inflamma-
tory ligands (TGF-b, ET-1, IL6, AngII, etc.) and also by mechan-
ical stretch (Hinz, 2007; Leask, 2010; Tomasek et al., 2002).
However, the vast majority of the literature in this area is domi-
nated by the role that canonical SMAD2/3-dependent TGF-b
signaling has in facilitating myofibroblast transformation (Hinz,
2007; Leask, 2010). In our current study, inhibition of canonical
signaling with SMAD6 or SMAD7 had no effect on myofibroblast
transformation or TRPC6 expression downstream of TGF-b, but
inhibition of noncanonical p38 signaling fully blocked TGF-
b-TRPC6-dependent myofibroblast transformation. These data
are consistent with previous work in fibroblasts in which TGF-b
induced a prolonged activation of p38 MAPK signaling that
increased collagen, fibronectin, and aSMA expression (Kim
et al., 2007; Meyer-Ter-Vehn et al., 2006). In fact, TGF-b-medi-
ated induction of aSMA stress fibers was blocked in MEFs
by deleting the downstream p38 target MK2 (MAPK-activated
protein kinase 2) (Sousa et al., 2007). Similar results were ob-
tained in glomerularmesangial cells when the upstream activatorier Inc.
Figure 7. The TRPC6-Calcineurin-NFAT Signaling Axis Is Necessary for Dermal Wound Healing
(A and B) (A) Photographs and (B) quantification of floating collagen gel matrix contraction rates seeded with Trpc6+/+ or Trpc6/ dermal fibroblasts at 48 hr
postinfection with AdTRPC6, AdDCnA, or treated with recombinant TGF-b. Arrows indicate the contracted diameter of the collagen matrix. *p < 0.05 versus
baseline; #p < 0.05 versus Trpc6+/+ TGF-b; yp < 0.05 versus TGF-b in Trpc6/; n = 3 independent experiments.
(C) Photographs of two full excision 6 mm dorsal dermal punch biopsies taken on 8- to 10-week-old Trpc6+/+ or Trpc6/ littermates 4 days after the biopsy.
Topical application of adenovirus containing GFP, TRPC6, or DCnA was applied to the site just after wounding.
(D) Time course of wound closure for Trpc6/ mice compared with Trpc6+/+ controls and treated with the indicated adenovirus. n = 8 mice per group. *p < 0.05
versus Trpc6+/+ (WT); #p < 0.05 versus Trpc6/ AdGFP; yp < 0.05 versus Trpc6/ alone or Trpc6/ AdGFP.
(E) Time course of wound closure for Trpc6+/+, Trpc6/, or Ppp3cb/ mice. n = 8 per group. *p < 0.05 versus Trpc6+/+ (WT); #p < 0.05 versus Ppp3cb/.
(F) Signaling model for myofibroblast transdifferentiation whereby noncanonical TGF-b signaling cascade through p38 signaling to SRF, mediates a transcrip-
tional upregulation of TRPC6 gene expression, enhancing Ca2+ entry leading to calcineurin (CnA) activation, sending NFAT to the nucleus to participate in
myofibroblast phenotypic conversion.
Graphical data represent the mean ± SEM.
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TRPC6 Pathway for Myofibroblast Transformationof p38, MKK3, was overexpressed causing the expression of
myofibroblast target genes (Wang et al., 2002).
The conventional paradigm is that AngII requires TGF-b sig-
naling to induce collagen production and fibrosis (Rosenkranz,
2004). However, in our studies ALK5 knockdown in cardiac fibro-
blasts did not block AngII-mediated myofibroblast transforma-
tion (Figure 4F). There are two potential hypotheses to explain
this result. First, AngII could activate noncanonical p38 signaling
through secretion of TGF-b that signals through TGFBR2 or
second, AngII could directly activate p38 MAPK signaling
through a GPCR pathway that is then fully capable of initiating
myofibroblast transformation through p38-TRPC6-calcineurin-
NFAT. There is supportive evidence for the later hypothesis
since TGF-b neutralizing antibodies are unable to block AngII
induction of myofibroblast markers (Leask, 2010) and Tgfbr1-
deficient hearts with pressure overload still activate noncanoni-
cal p38 signaling to drive cardiac remodeling (Koitabashi et al.,
2011). Similarly AngII in this study acted like TGF-b in promotingDevelopmTRPC6 gene expression and Ca2+ entry, which were both effec-
tively blocked with a p38 inhibitor.
Role of TRPC6, Ca2+ Influx, and Calcineurin
That enhanced Ca2+ influx elicits downstream myofibroblast
transformation is consistent with reports of Ca2+ driving both
differentiation and cytoskeletal rearrangement in other cell types
(Wang et al., 2009; Woelfle et al., 2010). However, in human atrial
fibroblasts isolated from atrial fibrillation patients there was
a higher level of myofibroblast differentiation due to increased
Ca2+ influx, albeit through the upregulation of a different TRP
family channel, TRPM7 (transient receptor potential melastatin
7; Mg2+ and Ca2+ entry) (Du et al., 2010). This study actually sup-
ports our current results since TRP family members can hetero-
oligomerize between families (Alessandri-Haber et al., 2009; Ma
et al., 2010), so it is possible that select TRPC and TRPM family
members generate complexes that mediate physiologic Ca2+
entry for myofibroblast transformation.ental Cell 23, 705–715, October 16, 2012 ª2012 Elsevier Inc. 713
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TRPC6 Pathway for Myofibroblast TransformationThe elevated SOCE attained from increased TRPC6 expres-
sion provides an ample Ca2+ signal to activate calcineurin-
NFAT signaling (Figure S3A). However, this does not imply that
SOCE is the mechanism behind TRPC6-mediated myofibroblast
conversion, as TRPC channels can cause Ca2+ entry in response
to receptor activation, stretch, and even other stress stimuli that
do not involve changes in intracellular Ca2+ stores. We simply
measured SOCE in our current study as an experimental surro-
gate for total TRPC6 ‘‘potential’’ for Ca2+ influx. While our results
showing that TRPC6-calcineurin-NFAT mediate myofibroblast
transformation have not been previously reported, work in
the heart and other tissues has shown that calcineurin-NFAT
signaling is activated by TRPC6 for other cellular functions (Ku-
wahara et al., 2006; Wu et al., 2010). Our data are most consis-
tent with TRPC6 directly providing Ca2+ in a local microenviron-
ment to calcineurin at the plasma membrane or in complex
between calcineurin-TRPC6 in mediating activation, as inhibition
of Inositol 1,4,5-trisphosphate (IP3) signaling with the IP3-sponge
did not affect TRPC6-dependent conversion of myofibroblasts
(data not shown).
If NFAT is involved as the primary mediator of calcineurin-
induced myofibroblast transformation, it probably functions in
accord with other transcriptional regulators, such as SRF and
the MRTFs (coregulators of SRF), and possibly SMAD proteins.
Indeed, mice lacking the MRTF-A protein were defective in
myofibroblast conversion and scar formation after MI injury
(Small et al., 2010). Notably, in an in vitro epithelial-mesenchymal
transition model, MRTF-dependent activation of aSMA tran-
scription required p38 signaling (Sebe et al., 2008), suggesting
a cooperative relationship between p38 signaling and MRTF
induction of fibrotic genes and myofibroblast function.
In summary, these findings define a role for TRPC6-calci-
neurin-NFAT signaling as a molecular circuit for myofibroblast
transformation and tissue repair. The identification of this sig-
naling arm offers an additional avenue for developing targeted
intervention points in fibrotic diseases. While calcineurin is
unlikely to be a therapeutic target given all the signaling inputs
it receives from other Ca2+ influx pathways, as well as its highly
diverse biologic functions, TRPC6 appears more dedicated to
this cellular differentiation mechanism and inhibitors could be
developed to reduce its activity.
EXPERIMENTAL PROCEDURES
Dermal Wound Healing Assay and Topical Adenoviral Application
For the dermal wound-healing model, mice underwent anesthesia, their
backs were prepared, and two 6 mm excisional wounds were created with a
disposable biopsy punch (Integra Miltex) on either side of the dorsal mid-
line.Woundsweremeasured andphotographeddaily in order to assesswound
retraction and health. In some experiments, biopsies were made and topically
treated with the following adenoviral vectors for 15 min before applying
a Tegaderm adhesive, which held the virus in the wounded area. Wound
photographs were analyzed by ImageJ software (NIH) to measure surface
areas. All mouse protocols were approved by the Institutional Animal Care
and Use Committee of Cincinnati Children’s Hospital Medical Center.
Myocardial Infarction and Echocardiography
To create MIs, 10-week-old mice were subjected to permanent occlusion of
the left coronary artery after a thoracotomy procedure where the left coronary
artery was ligated with 8-0 suture. M-mode echocardiography (Hewlett Pack-
ard SONOS 5500) was performed in anesthetized mice with a 15 MHz714 Developmental Cell 23, 705–715, October 16, 2012 ª2012 Elsevtransducer at 3 and 7 days after MI surgery to assess cardiac function and
ventricular geometry anesthesia.
TGF-b/AngII Treatments, Adenoviral Gene Transfer, and shRNA
Lentiviral Knockdown
Application of recombinant porcine TGF-b (10 ng/ml, R&D System) or AngII
(100 nM, Sigma) was used to induce myofibroblast transformation. The p38
inhibitor (SB731445) was delivered in 50 nM doses. For experiments that
required adenoviral gene transfer, fibroblasts were incubated in adenovirus
for 24 hr at which time the media was changed and the cells were typically
incubated for an additional 24–48 hr. For knockdown of the SRF gene rat
cardiac fibroblasts were adenovirally transduced with shRNA constructs
shGFP (control) or shSRF. At 2 days after shSRF/shGFP gene transfer, fibro-
blasts were adenovirally infected with AdTRPC6 or AdDCnA or pharmacolog-
ically treated with TGF-b (10 ng/ml) or AngII (100 nM). For knockdown of
the ALK5 gene (TGF-b receptor 1, NM_009370) Mission shRNA lentivirus
(Sigma, TRCN0000022479, 80, 81, 82, 83) was obtained and knockdown
was achieved at 4 days after gene transfer.
TRPC6 Luciferase Reporter and Luciferase Assay
Three DNA fragments,215 to +1, 215 to +1 with a mutated CArG site, and
1187 to +1, of themurine TRPC6 promoter were individually subcloned into the
XhoI and HindIII sites of the pGL3 promoter luciferase plasmid (Promega) to
make TRPC6 reporter constructs. The proximal and highly conserved
consensus CArG site at 123 (50 CCTTTAAAGG 30) in the TRPC6 promoter
was mutated to TGTGCGAAGG (Genewiz Inc.). For luciferase assays, rat
cardiac fibroblasts were maintained in media + 1% serum and transiently co-
transfected with a TRPC6 luciferase reporter (Mirus, Trans-IT) and either a bgal
or SRF plasmid. In addition, some transfected fibroblasts were also treated
with TGF-b (10 ng/ml) or p38 inhibitor (50 nM). Luciferase activity was
measured 48 hr posttransfection.
Collagen Gel Contraction Assay
Fibroblasts at 70% confluence were adenovirally infected if experimentally
required or grown in culture media for 24 hr. Fibroblasts were harvested
from a confluent monolayer by Trypsin-EDTA digestion (0.25%), pelleted,
and resuspended in DMEM with 1% serum. Fibroblasts were then seeded
into collagen matrices such that each gel contained 40,000 fibroblasts and
cast in 24-well plates. The collagen gels were released from the edges and
floating in DMEMwith 1% serum. ImageJ software (NIH) was used to calculate
the surface area, which are reported as values normalized to the initial size of
the gel.
Statistical Tests
Statistical significance was determined by ANOVA and Newman-Keuls pair-
wise comparisons for multivariate experiments and t test for experiments
with two groups.
See Supplemental Experimental Procedures for a full listing of the experi-
mental procedures.
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